Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Balance Sheet: Assets 
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Edwards Lifesciences Corp., consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Cash and cash equivalents 862,800 1,506,900 1,312,800 1,174,200 1,183,200 1,024,000 903,500 662,900 1,179,100 1,186,600 726,800 709,200 714,100 1,261,300 1,226,400 1,227,000 818,300 630,300 508,200 819,300
Short-term investments 604,000 287,800 248,400 156,400 219,400 271,300 260,300 368,200 337,800 170,300 207,500 253,800 242,400 334,400 174,400 272,300 519,200 772,500 623,600 98,900
Accounts receivable, net of allowances 582,200 600,600 640,500 586,600 514,600 549,700 — — — — — — — — — — — — — —
Other receivables 82,700 63,600 59,800 77,700 88,200 122,000 — — — — — — — — — — — — — —
Accounts and other receivables, net of allowances (legacy) — — — — — — 567,900 585,100 599,100 570,000 609,600 578,000 537,300 530,100 520,100 446,800 462,200 475,000 510,700 510,200
Inventories 726,700 737,800 759,500 767,900 802,300 773,300 735,100 662,200 640,900 611,100 624,900 630,900 607,000 583,800 568,100 573,900 554,900 538,400 491,600 431,400
Prepaid expenses 85,200 76,900 68,600 77,300 75,100 68,600 57,300 65,800 59,100 57,300 55,700 55,400 54,300 52,600 69,900 78,000 60,600 52,800 54,100 53,000
Other current assets 237,100 241,900 233,300 229,100 208,200 171,500 166,200 163,700 168,000 144,400 130,200 141,500 131,800 150,400 137,100 118,900 116,900 97,400 95,200 105,600
Current assets 3,180,700 3,515,500 3,322,900 3,069,200 3,091,000 2,980,400 2,690,300 2,507,900 2,984,000 2,739,700 2,354,700 2,368,800 2,286,900 2,912,600 2,696,000 2,716,900 2,532,100 2,566,400 2,283,400 2,018,400
Long-term investments 1,834,200 1,282,000 1,014,200 802,200 801,600 599,000 594,400 587,800 585,500 386,000 412,900 453,700 506,300 479,000 470,400 532,100 567,000 567,500 551,500 519,000
Property, plant, and equipment, net 1,546,600 1,464,600 1,445,800 1,417,900 1,395,200 1,276,300 1,195,600 1,100,600 1,060,300 973,600 931,100 892,200 867,500 826,100 770,200 711,600 679,700 649,600 627,900 588,800
Operating lease right-of-use assets 92,100 84,800 84,600 88,500 94,200 89,500 84,700 75,500 80,100 73,300 71,200 69,900 — — — — — — — —
Goodwill 1,167,900 1,170,400 1,171,800 1,170,800 1,173,200 1,170,000 1,167,700 1,166,200 1,167,700 1,156,600 1,173,900 1,103,400 1,112,200 1,122,300 1,118,600 1,144,800 1,126,500 980,500 965,100 945,200
Other intangible assets, net 323,600 325,300 327,000 330,300 331,400 332,400 333,500 334,800 336,500 381,100 385,600 341,300 343,200 467,900 466,000 480,500 468,000 414,900 408,600 402,100
Deferred income taxes 246,700 184,000 190,500 209,300 230,900 215,200 204,100 158,000 172,200 155,800 163,800 164,500 174,000 115,100 130,100 181,400 213,600 197,100 185,200 179,100
Other assets 110,800 133,700 105,300 125,500 119,600 138,000 153,800 145,300 101,800 100,200 80,300 75,500 33,600 35,200 34,800 57,800 108,900 112,400 116,800 127,800
Long-term assets 5,321,900 4,644,800 4,339,200 4,144,500 4,146,100 3,820,400 3,733,800 3,568,200 3,504,100 3,226,600 3,218,800 3,100,500 3,036,800 3,045,600 2,990,100 3,108,200 3,163,700 2,922,000 2,855,100 2,762,000
Total assets 8,502,600 8,160,300 7,662,100 7,213,700 7,237,100 6,800,800 6,424,100 6,076,100 6,488,100 5,966,300 5,573,500 5,469,300 5,323,700 5,958,200 5,686,100 5,825,100 5,695,800 5,488,400 5,138,500 4,780,400

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Edwards Lifesciences Corp. current assets increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
Property, plant, and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Edwards Lifesciences Corp. property, plant, and equipment, net increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Edwards Lifesciences Corp. long-term assets increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Edwards Lifesciences Corp. total assets increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Edwards Lifesciences Corp. cash and cash equivalents increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
Short-term investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. Edwards Lifesciences Corp. short-term investments increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Accounts receivable, net of allowances Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Edwards Lifesciences Corp. accounts receivable, net of allowances decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Accounts and other receivables, net of allowances (legacy) The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Edwards Lifesciences Corp. inventories decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.